To provide information to researchers and healthcare decision makers about economic evaluation methods that can be applied to estimate the value of new vaccination programs against infectious diseases including cost-effectiveness analysis (CEA), mathematical programming, and return-on-investment analysis. In addition the task force will:
- Provide a set of recommendations for good practice for performing and presenting each type of analysis;
- Assess the relevance of each method for different decision makers;
- Assess under which circumstances the different approaches may be complementary to each other showing a more complete value picture of the new vaccines.
The recommendations for CEA will not duplicate the ones from previous ISPOR task forces on CEA but will reference these publications and focus on those elements of the CEA methods that are specific for vaccines.
There are a variety of methods currently used to estimate the economic value of vaccination programs without a clear understanding of the applicability of the method proposed to the specific jurisdiction or to the remit of the decision maker or to the characteristics of the disease being prevented.
Clear guidance and recommendations for good research practice will provide researchers and healthcare decision makers with: (a) An understanding of all the different techniques available to value the economic benefit of vaccines and the types of outcomes produced by each technique (b) An understanding of the need to link jurisdiction income level and decision maker remit with an appropriate economic assessment to assess the value of new vaccines (c) A set of clear guidelines and recommendations for good research practice for performing economic evaluations using methods that have been frequently used and their applicability to an assessment of the value of vaccination programs in high- and low-income countries. (d) A description of the strengths and weaknesses of each economic evaluation method focusing on structural issues, input data availability or credibility, and usefulness for the decision maker.
Josephine Mauskopf, PhD, Vice President, Health Economics, RTI Health Solutions, NC, USABaudouin Standaert, MD, PhD, Health Economics, GSK Vaccines, Belgium
Mark Connolly, PhD, Guest Researcher, University of Groningen, the Netherlands and Managing Director, Global Market Access Solutions LLC, Geneva, Switzerland
Tony Culyer, CBE, BA, Emeritus Professor, University of York, York, UK
Lou Garrison, PhD, Professor, Department of Pharmacy, University of Washington, Seattle, WA, USA
Raymond Hutubessy, PhD, MSc, Senior Health Economist, Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland
Mark Jit, BSc, PhD, MPH, Reader, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine and Public Health, Faculty of Epidemiology and Population Health, London, UK
Richard Pitman, PhD, BSc, Lead Epidemiologist, ICON, Oxfordshire, UK
Paul Revill, MSc, Research Fellow, University of York, Centre for Health Economics, York, UK
Hans Severens, PhD, Professor of Evaluation in Health Care, iBMG - Institute of Health Policy & Management and iMTA - Institute of Medical Technology Assessment, Erasmus University, Rotterdam, the Netherlands